On the other hand, The p53-MDM2 interaction is a pivotal event involved in tumor progression [29], and targeting the MDM2-p53 interaction by small molecules to reactivate p53 has emerged as a promising new strategy for cancer therapy [30]. This evidence concerns the gene MDM2 and cancer.